Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

SELL
$1.35 - $3.12 $5.86 Million - $13.5 Million
-4,337,167 Reduced 86.74%
662,833 $914,000
Q2 2023

Aug 14, 2023

BUY
$1.64 - $4.85 $8.2 Million - $24.3 Million
5,000,000 New
5,000,000 $12.5 Million

Others Institutions Holding TCRX

About TScan Therapeutics, Inc.


  • Ticker TCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,929,800
  • Market Cap $31.6M
  • Description
  • TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...
More about TCRX
Track This Portfolio

Track Eco R1 Capital, LLC Portfolio

Follow Eco R1 Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eco R1 Capital, LLC with notifications on news.